Business
ScreenPoint Medical Secures $16M to Lead the Next Phase of AI in Breast Cancer Care
ScreenPoint Medical, a leader in artificial intelligence solutions for breast cancer detection and risk assessment, today announced $14 million in new funding from existing investors, global software investor Insight Partners and Siemens Healthineers, in addition to $2 million in non-dilutive research grants.
About this update from Siemens Healthineers Ag
[{"type":"text","content":"NIJMEGEN, Netherlands, April 17, 2026 /PRNewswire/ -- ScreenPoint Medical, a leader in artificial intelligence solutions for breast cancer detection and risk assessment, today announced $14 million in new funding from existing investors, global software investor Insight Partners and Siemens Healthineers, in addition to $2 million in non-dilutive research grants.","length":364,"tagName":"p"},{"type":"image","alt":"(PRNewsfoto/ScreenPoint Medical)","displaySize":"","headline":null,"caption":"(PRNewsfoto/ScreenPoint Medical)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":146,"url":"https://media.zenfs.com/en/prnewswire.com/5c3f2922248c17950f36fe475f7a4e64"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/cX_QO.lJk8kQuyceUVVBWw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTI1Nw--/https://media.zenfs.com/en/prnewswire.com/5c3f2922248c17950f36fe475f7a4e64","width":400,"height":146}},"href":"https://mma.prnewswire.com/media/1582198/ScreenPoint_Medical_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"The investment reflects continued support from ScreenPoint Medical's long-term partners, commercial momentum within the United States and globally, and confidence in the company's vision of precision and personalised breast cancer care, from prevention and screening to treatment and beyond. Transpara® Breast AI solutions are deployed in 30+ countries with over 12 million mammograms processed to date, and they are used by many of the world's leading healthcare systems, screening programmes, universities, and imaging groups.","length":540,"tagName":"p"},{"type":"text","content":"This announcement also comes as the company's solutions have been the focus of groundbreaking new research this year:","length":121,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"The first randomised controlled trial (RCT) in breast cancer AI (MASAI) published its final results[i] on the use of Transpara in The Lancet, finding "consistently favourable outcomes compared with standard double reading" including significant impacts on cancer detection and workload reduction.","length":307,"tagName":"p"}]},{"val":[{"type":"text","content":"New prospective research[ii] on "autonomous" AI published in Nature Medicine demonstrated that Transpara can safely r...